CN Patent

CN105392483B — 用于抑制磷酸盐转运的nhe3结合化合物和方法

Assigned to Ardelyx Inc · Expires 2019-03-15 · 7y expired

What this patent protects

提供具有作为磷酸盐转运抑制剂，包括胃肠道和肾脏中磷酸盐转运的抑制剂的活性的NHE3结合和/或NHE3调节剂，和用于其作为治疗剂或预防剂的用途的方法。

USPTO Abstract

提供具有作为磷酸盐转运抑制剂，包括胃肠道和肾脏中磷酸盐转运的抑制剂的活性的NHE3结合和/或NHE3调节剂，和用于其作为治疗剂或预防剂的用途的方法。

Drugs covered by this patent

tenapanor-hydrochloride (TENAPANOR HYDROCHLORIDE)

Patent Metadata

Patent number: CN105392483B
Jurisdiction: CN
Classification: —
Expires: 2019-03-15
Drug substance claim: No
Drug product claim: No
Assignee: Ardelyx Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.